(Health-NewsWire.Net, April 02, 2015 ) Dallas, TX -- Global Markets Direct’s, Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection – Pipeline Review, H1 2015′, provides an overview of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection and special features on late-stage and discontinued projects.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Order a Purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=328261 . (This is a premium report priced at US$2000 for a single user License.)
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
• The report reviews key players involved in the therapeutics development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products
• The report provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection
Inquire for discount at http://www.rnrmarketresearch.com/contacts/discount?rname=328261 .
Reasons to Buy:
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection
• Devise corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection pipeline depth and focus of Indication therapeutics
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Explore more reports on Pharmaceuticals at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research